TSX: HSM     OTC: HSDT

Call us: +1 877-564-0008

newsBanner

HELIUS MEDICAL TECHNOLOGIES ANNOUNCES APPOINTMENT OF JOYCE LAVISCOUNT AS NEW DIRECTOR

(Newtown PA) – March 3, 2015 – Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) (“HMT”, “Helius” or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, today announced that its board of directors has appointed Joyce LaViscount as a new member.  Her appointment is effective March 2, 2015.

“We are delighted to welcome Joyce to Helius’ board of directors,” said Philippe Deschamps, Chief Executive Officer of Helius. “We are confident that her 30 years of experience and expertise in finance and operations in the pharmaceutical and life science industry will prove a valuable asset to the company.”

Ms. LaViscount currently serves as the Chief Financial Officer of MediMedia Pharmaceutical Solutions, the pharmaceutical division of MediMedia USA.  Prior to joining MediMedia, Ms. LaViscount was Executive Director/Group Controller North America for Aptalis Pharmaceuticals and spent more than 5 years at Endo Pharmaceuticals in a variety of roles including Chief Accounting Officer, VP-Investor Relations and Corporate Communications and VP Finance Operations as well as operational roles in Sales Operations and Training and Corporate Strategy Development.  Ms. LaViscount’s pharmaceutical industry experience also includes more than 15 years in finance at Bristol-Myers Squibb and Pharmacia.  Ms. LaViscount began her career with Ernst & Young and is a New Jersey Certified Public Accountant.

With this appointment, the board of directors of the Company now consists of Philippe Deschamps, Yuri Danilov, Mitch Tyler, Edward M. Straw, Savio Chiu and Joyce LaViscount.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance of the PoNS™ device. For more information, please visit http://www.heliusmedical.com.

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Safe Harbor Statement

All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.

# # #

Corporate Contact:
Phil Deschamps

614-596-2597

pdeschamps@heliusmedical.com

US Investor Relations Contact:

Todd James

646-378-2926

tjames@troutgroup.com

Canadian Investor Relations:

778-588-7144

info@heliusmedical.com

Media Contact:

Becky Kern

914-772-2310

bkern@heliusmedical.com